文献速递儿童感染儿童呼吸

奥司他韦治疗儿童流感疑似病例的多中心随机开放试验

[Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial].
PubMed 文献 · Zhonghua Er Ke Za Zhi · 2017-01-01

该多中心随机开放试验纳入2015年4至7月广东省5所医院门诊的229例儿童流感疑似病例,比较奥司他韦组(114例)与对照组(115例)的疗效与安全性。总体人群中两组疾病持续时间和发热持续时间差异无统计学意义,但73例流感病毒检测阳性患儿中奥司他韦组疾病持续时间显著缩短,完成疗程者发热持续时间显著缩短;奥司他韦组不良反应发生率10%高于对照组2%,多为消化道症状。

要点

  • 流感病毒检测阳性患儿中奥司他韦可显著缩短疾病持续时间。
  • 完成奥司他韦全程治疗者发热持续时间显著缩短。
  • 奥司他韦不良反应多为消化道症状,发生率10%。

核心结论

  • 疑似流感患儿总体中奥司他韦缩短疾病和发热持续时间但差异无统计学意义。
  • 流感病毒检测阳性患儿中奥司他韦显著缩短疾病持续时间。
  • 完成奥司他韦疗程者发热持续时间显著缩短且不良反应轻微。

研究设计与样本

  • 多中心随机开放标签试验,2015年4至7月广东省5所医院门诊纳入229例儿童流感疑似病例。
  • 奥司他韦组114例给予奥司他韦30-75 mg每日两次连用5天,对照组115例给予症状缓解药物5天。

主要发现

  • 229例中73例(31.9%)流感病毒检测阳性。
  • 总体229例中奥司他韦组与对照组疾病持续时间中位数69.9小时(95%CI 65.3-91.5)比75.4小时(95%CI 63.9-91.7),差异无统计学意义。
  • 总体229例中奥司他韦组与对照组发热持续时间中位数40.4小时(95%CI 31.5-53.4)比44.0小时(95%CI 33.2-50.0),差异无统计学意义。
  • 73例阳性患儿中奥司他韦组发热持续时间中位数32.8小时(95%CI 24.0-47.0)与对照组55.8小时(95%CI 43.6-78.3)差异无统计学意义。

关键数值与推荐

  • 73例阳性患儿中完成治疗方案的60例(奥司他韦组38例,对照组22例)发热持续时间中位数34.8小时(95%CI 24.0-48.5)显著短于对照组53.3小时(95%CI 43.6-104.0),P<0.05。
  • 不良反应发生率奥司他韦组10%高于对照组2%,P<0.05,主要为消化道症状(腹痛、腹泻、食欲差、呕吐)。

临床怎么用

  • 对流感病毒检测阳性的患儿使用奥司他韦可缩短疾病持续时间。
  • 建议完成奥司他韦全程治疗以利于缩短发热持续时间。
  • 用药期间注意消化道不良反应,多可自行缓解。

局限性

  • 开放标签设计可能引入偏倚。
  • 流感病毒检测阳性率31.9%,阳性亚组样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of oseltamivir in the treatment of suspected influenza in children. Method: A multicenter, randomized and open-label trial was conducted among 229 individuals with suspected influenza which were collected from the clinic of 5 hospitals in Guangdong province (Guangzhou Women and Children's Medical Center, Shenzhen Baoan District Maternity and Child Care Service Center, the Second Affiliated Hospital of Shantou University Medical College, Dongguan Maternity and Child Care Service Centre, Yuexiu District Children's Hospital of Guangzhou) from April to July 2015. They were randomized either to oseltamivir group (oseltamivir 30-75 mg, twice daily for 5 days) or control group who were given symptom relief medicines for 5 days. Result: No significant difference was found between two groups in influenza symptoms of the patients before the treatment(P>0.05). Altogether 229 individuals (114 in oseltamivir group, 115 in control group) were analyzed for efficacy, in which 73 individuals (42 oseltamivir, 31 control), 31.9%, were identified as influenza-infected through laboratory test. No significant difference was found between the two groups in the duration of fever although shortened. In the 229 individuals , the cumulative alleviation proportion between oseltamivir and control group was not significantly different (P>0.05): the median duration of illness was 69.9 hours (95% CI 65.3-91.5) in oseltamivir group and 75.4 hours (95%CI 63.9-91. 7) in control group; the median duration of fever was 40.4 hours (95%CI 31.5-53.4) in oseltamivir group and 44.0 hours (95%CI 33.2-50.0) in control group. In the 73 individuals, the cumulative alleviation proportion between oseltamivir and control group was significantly different (P<0.05). The median duration of illness was 61.2 hours (95%CI 48.0-121. 0) in oseltamivir group, being significantly shorter than that of 116.0 hours (95%CI 91.5-175.0) in control group. But it was not significantly different that the median duration of fever was 32.8 hours (95%CI 24.0-47.0 ) in oseltamivir group and 55.8 hours (95%CI 43.6-78.3 ) in control group (P>0.05). And the median duration of fever in 60 individuals (38 oseltamivir, 22 control) was significantly different between two groups(P<0.05), who had finished a course of taking oseltamivir in the 73 individuals, 34.8 hours (95%CI 24.0-48.5 ) in oseltamivir group being significantly shorter than that of 53.3 hours (95%CI 43.6-104.0 ) in control group. There was certain difference in side effects rate between the two groups (oseltamivir 10%, control 2%, P<0.05). The main side-effects were gastrointestinal symptoms (stomachache, diarrhea, poor appetite, vomiting). Conclusion: The duration of illness and fever in suspected influenza patients treated with oseltamivir was shorter than those in the patients treated with no oseltamivir, the difference was not statistically significant, when 31.9% was confirmed with positive result of virus test in suspected influenza in children. But in these patients with positive result of virus test, the duration of illness was significantly shortened with treatment with oseltamivir as compared with no treatment with oseltamivir, and it would be better if full oseltamivir course was completed for reducing the duration of fever. Oseltamivir treatment was safe with mild side effects. 目的: 研究磷酸奥司他韦颗粒剂治疗儿童流感疑似病例的有效性及安全性。 方法: 采用多中心、随机、开放性研究。收集广东省5所医院(广州市妇女儿童医疗中心、深圳市宝安区妇幼保健院、汕头大学医学院第二附属医院、东莞市妇幼保健院、广州市越秀区儿童医院) 2015年4月至7月门诊收治的儿童流感疑似病例229例,随机分为2组。对照组115例,给予愈酚伪麻口服溶液作为基础治疗,连续给药5 d;试验组114例,给予基础治疗加上磷酸奥司他韦颗粒剂,同样连续给药5 d。观察磷酸奥司他韦颗粒剂疗效和安全性。 结果: (1)治疗前两组疑似病例在病情严重程度上差异无统计学意义。治疗后试验组比对照组,在疾病持续时间(h)[69.9(95%CI 65.3~91.5)比75.4(95%CI 69.9~91.7)]、发热持续时间(h)[40.4 (95%CI 31.5~53.4)比44.0(95%CI 33.2~50.0)]上差异虽无统计学意义,但均有所缩短。(2)229例中有73例(31.9%)流感病毒检测阳性,治疗后试验组(42例)比对照组(31例),疾病持续时间缩短约55 h,流感症状持续时间缩短近60 h;两组差异有统计学意义(P<0.05)。发热持续时间(h)[32.8 (95%CI 24.0~47.0)比55.8(95%CI 43.7~78.3)]虽缩短23 h,但差异无统计学意义(P>0.05)。(3)73例流感病毒检测阳性病例中完成治疗方案的患儿共60例,试验组(38例)比对照组(22例)发热持续时间(h)[34.8 (95%CI 24.0~48.5)比53.3(95%CI 43.6~104.0)]缩短近19 h,差异有统计学意义(P<0.05)。(4)不良反应发生率:试验组(10%)比对照组(2%),差异有统计学意义(P<0.05),不良反应多为消化道症状,多可自行缓解。 结论: 2015年4至7月广东省5所医院门诊收治的儿童流感疑似病例流感病毒阳性率31.9%;疑似病例中,予磷酸奥司他韦颗粒剂治疗的与未予磷酸奥司他韦颗粒剂治疗的,在疾病持续时间、发热持续时间虽统计学未达显著界值,但数值上均较其缩短;流感病毒阳性病例中,予磷酸奥司他韦颗粒剂治疗的比未予磷酸奥司他韦颗粒剂治疗的,疾病持续时间明显缩短;完成用药疗程更有利于缓解发热。且不良反应小,应用安全。.

来源:Zhonghua Er Ke Za Zhi,查看原文。版权归原作者所有。

引用

  1. He CH, Liu CY, Lin GY, et al. [Efficacy and safety of oseltamivir in children with suspected influenza: a multicenter randomized open-label trial]. Zhonghua Er Ke Za Zhi. 2017. PMID: 28592016. doi:10.3760/cma.j.issn.0578-1310.2017.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。